Search results
Results From The WOW.Com Content Network
Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. The company went public in 1973.
Volini is a brand of pain relief medical spray and cream manufactured, marketed and sold by Sun Pharma in India. [1] [2] The product was created by Ranbaxy Laboratories, but has been owned by Sun Pharma ever since Ranbaxy was acquired by the latter in 2014. [3]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
On April 20, 2015, the company announced it had sold off the 8.9% stake in Sun Pharmaceutical Industries it acquired when acquiring Ranbaxy, raising $3.2 billion. [21] It transferred 41 of its products in Japan to Alfresa Holdings Corporation for JPY 4.2 billion in 2018 in order to focus on oncology. [22]
Crotamiton is marketed under the trade names Eurax, which is manufactured by Ranbaxy Laboratories in the United States, and GlaxoSmithKline in the United Kingdom, and Euracin, which is manufactured by Green Cross in South Korea. In Germany, it is marketed under the brand name Crotamitex. In India, it is sold as Eurax by Ranbaxy Laboratories.
Arterolane, also known as OZ277 or RBx 11160, is an antimalarial compound marketed by Ranbaxy Laboratories. [1] It was discovered by US and European scientists coordinated by the Medicines for Malaria Venture (MMV). [2]
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the pharmaceutical giant offers investors a 4.3% dividend yield backed by a ...
The company was founded in 1995 by brothers Shivinder Mohan Singh and Malvinder Mohan Singh as Specialty Ranbaxy Limited (SRL), a 50:50 joint venture between Ranbaxy Laboratories and US-based Specialty Laboratories. [5] [6] It became the first pathology company in India to receive accreditation from National Accreditation Board. [7]